Novel Biomarker Test with Treatment, to Predict and Prevent Miscarriage and Adverse Birth Outcomes in Ethnically Diverse Patient Populations.

A prototype blood test is being manufactured and trialled to predict and prevent miscarriages and other adverse birth outcomes, with a specific focus on Black and Asian patients who face higher risks. This matters because miscarriage and complications like preterm birth affect thousands of pregnancies each year, yet current prediction tools are limited and often fail to account for ethnic differences in risk. The project builds on earlier feasibility work to produce a final-format diagnostic test, then validate it in a randomised controlled trial. An economic analysis will assess the test’s value to the NHS by calculating savings from fewer miscarriages and reduced long-term costs of adverse outcomes. If successful, the test could become a routine part of antenatal care, allowing early identification of high-risk pregnancies and targeted treatment. This would reduce preventable harm to mothers and children, and lower healthcare costs. The project also includes documentation needed for regulatory clearance, moving the test toward clinical use. For a funder focused on maternity outcomes, this work directly addresses a persistent gap in equitable, evidence-based care.